MedPath

Combining Language Therapy With rTMS in Aphasia

Not Applicable
Completed
Conditions
Aphasia
Interventions
Behavioral: Intensive Language-Action Therapy (ILAT)
Device: Repetitive navigated Transcranial Magnetic Stimulation during naming training
Registration Number
NCT03629665
Lead Sponsor
Paula Heikkinen
Brief Summary

With the present RCT, the investigators aimed at finding an optimal protocol for the neurorehabilitation of chronic post-stroke aphasia by combining two promising methods, ILAT (Intensive language action therapy) and 1-Hz rTMS to the right-hemispheric homologue of the anterior language area of Broca (pars triangularis), thus taking advantage of recent research in speech and language sciences, neurorehabilitation and brain research.

Detailed Description

New neuromodulation technologies, such as transcranial magnetic stimulation (TMS), are promising tools for neurorehabilitation, aphasia therapy included. Combined with behavioral techniques, Intensive Language-Action Therapy (ILAT), TMS could substantially amplify the beneficial effect of such behavioral therapy alone.

In this randomized study of 17 subjects with post-stroke aphasia in the chronic stage will be studied the combined effect of ILAT and 1-Hz placebo-controlled navigated repetitive TMS (rTMS) to the right-hemispheric inferior frontal cortex (pars triangularis). Participant will be randomized to groups A and B. Participants in group A will receive a 2-week period of rTMS during naming training where they name pictures every ten second displayed on the screen, followed by 2-weeks of rTMS and naming combined with ILAT. Those in group B will receive the same behavioral therapy but TMS is replaced by sham stimulation.

Language performance will be measured before, during and after the interventions for 3 months.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria
  • age between 18 and 75 years
  • presence of a single clinically documented stroke
  • chronic stage (at least 12 months post-stroke)
  • aphasia documented using the WAB test
  • no recurring utterances or severe global (total) aphasia
  • residual ability to understand simple task instructions
  • availability of information about medication
  • right-handedness
  • native speakers of Finnish.
Exclusion Criteria
  • severe global (total) aphasia (Boston naming test less 3 points)
  • neglect, agnosia, severe vision impairment or hearing loss
  • severe attention or memory deficits
  • left-handedness
  • cardiac pacemaker or other stimulators
  • diagnosis of severe diabetes or severe depression
  • additional neurological diagnoses
  • other interventions, including speech therapy, in the same time period

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
sham rTMS and naming combined with ILATIntensive Language-Action Therapy (ILAT)Interventions: sham Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
rTMS and naming combined with ILATIntensive Language-Action Therapy (ILAT)Interventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
rTMS and naming combined with ILATRepetitive navigated Transcranial Magnetic Stimulation during naming trainingInterventions: Repetitive navigated Transcranial Magnetic Stimulation, picture naming and Intensive Language Action Therapy
Primary Outcome Measures
NameTimeMethod
The Western Aphasia BatteryChange in AQ performed at weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion

aphasia quotient (AQ) measurement

Secondary Outcome Measures
NameTimeMethod
The Action naming testChange in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion

picture naming ability

The Boston naming testChange in picture naming ability between weeks 1 (baseline), 4 and 7 and follow up 3 months after therapy completion

picture naming ability

© Copyright 2025. All Rights Reserved by MedPath